Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Lowering LDL cholesterol by statins has been proven to be associated with reduction of
proinflammatory regulators e.g. activation of the transcription factor NF-ĸB. Up to now the
effects of newer cholesterol lowering agents such as ezetemibe with respect to their
anti-inflammatory potential are less intensively studied. Therefore the investigators
analyzed whether equipotent LDL-lowering therapy with simvastatin alone and in combination
with ezetimibe have comparable effects on NF-ĸB-activation in peripheral blood mononuclear
cells (PBMCs) of patients with type 2 diabetes.